RxDoctor Payments Data

Justin Merkow, MD

Pain Medicine · Englewood, CONPI 1578829016

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,164 of the $24,403 with a category attached, or 62.1%. 36 manufacturers reported payments, led by Abbott at 27.8% of the total. Reporting peaked in 2023 at $9,996 and has fallen 82.7% since, to $1,730 in 2025. Among pain medicine clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,403in general payments, 2019–2025

Across 385 payments — averaging $63.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Boston Scientific$4K
  • Medtronic$2K
  • Nevro Corp.$2K
  • MML US, Inc.$1K
  • Relievant Medsystems, Inc.$1K
  • plus $7K from 30 others

What the payments were for

  • Consulting fees$4,40018%
  • Travel & lodging$4,39518%
  • Food & beverage$15,16462%
  • Education$4442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,403 in reported general payments places this provider in the 90th percentile of 96 pain medicine providers in Colorado.

See all pain medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$352,486
Medicare patients
655
Services billed
3,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl15$11,972
Fentanyl13$5,237
Buprenorphine16$4,378
Gabapentin150$2,469
Pregabalin80$2,254
Oxycodone Hcl135$2,198
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$1,316
Methocarbamol73$1,224
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen44$1,192
Lidocaine12$957
Morphine Sulfate ErMorphine Sulfate27$848
Tizanidine Hcl60$691
Cyclobenzaprine Hcl46$644
Hydromorphone Hcl29$413
Tramadol Hcl34$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$405$11,97215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 96 pain medicine providers in Colorado.

Other pain medicine in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →